^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Papitrol (tirvalimogene teraplasmid) (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety results of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab administration in patients with HPV 16- and/or 18- positive advanced cervical cancer: Phase II interim analysis results (KEYNOTE-567).
Excerpt:
GX-188E vaccine combined with pembrolizumab in recurrent/advanced cervical cancer was safe and tolerable, and showed an enhanced clinical response rate compared with pembrolizumab alone in particular in patients with PD-L1 positive, HPV-16 and squamous cell carcinoma.
DOI:
10.1200/JCO.2021.39.15_suppl.5511
Trial ID:
